NCT03989466 2024-10-10Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaM.D. Anderson Cancer CenterPhase 1 Completed15 enrolled
NCT02646748 2022-03-31Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsIncyte CorporationPhase 1 Completed159 enrolled